Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare ConferencePRNewsWire • 05/04/22
Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022PRNewsWire • 04/28/22
Earnings Preview: Vanda Pharmaceuticals (VNDA) Q1 Earnings Expected to DeclineZacks Investment Research • 04/27/22
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsPRNewsWire • 02/23/22
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022PRNewsWire • 02/17/22
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in GastroparesisPRNewsWire • 02/04/22
Vanda Pharmaceuticals Announces Participation at November 2021 Investor ConferencesPRNewsWire • 11/10/21
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Vanda Pharmaceuticals (VNDA) Misses Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/03/21
Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021PRNewsWire • 10/27/21
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/20/21
Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual ConferencePRNewsWire • 09/08/21
Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 08/05/21
Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia PatientsPRNewsWire • 08/03/21